C4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	35.04	35.95	35.58	20.76	31.1	45.79
Revenue Growth	2.33%	1.02%	71.44%	-33.25%	-32.08%	37.93%
Cost of Revenue	4.79	8.98	12.54	117.71	117.84	94.67
Gross Profit	30.25	26.97	23.05	-96.95	-86.75	-48.88
Selling, General & Admin	36.02	36.2	42.12	42.08	42.79	33.25
Research & Development	95.26	95.26	98.1	-	-	-
Operating Expenses	131.29	131.46	140.22	42.08	42.79	33.25
Operating Income	-101.03	-104.49	-117.18	-139.03	-129.53	-82.13
Interest Expense	-	-	-	-1.37	-2.22	-2.15
Interest & Investment Income	7.82	7.61	9.03	6.03	4.29	2.27
EBT Excluding Unusual Items	-93.22	-96.88	-108.14	-134.38	-127.46	-82.01
Merger & Restructuring Charges	-	-	-2.44	-	-	-
Gain (Loss) on Sale of Investments	2.65	2.74	5.4	3.78	-0.71	-1.88
Asset Writedown	-10.73	-10.73	-	-	-	-
Other Unusual Items	-	-	-	-0.62	-	-
Pretax Income	-101.3	-104.87	-105.19	-131.21	-128.18	-83.89
Income Tax Expense	0.12	0.12	0.13	1.28	-	-
Net Income	-101.42	-104.99	-105.32	-132.49	-128.18	-83.89
Net Income to Common	-101.42	-104.99	-105.32	-132.49	-128.18	-83.89
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	112	83	69	50	49	46
Shares Outstanding (Diluted)	112	83	69	50	49	46
Shares Change	58.30%	19.49%	39.75%	1.59%	6.13%	304.93%
EPS (Basic)	-0.91	-1.27	-1.52	-2.67	-2.62	-1.82
EPS (Diluted)	-0.91	-1.27	-1.52	-2.67	-2.62	-1.82
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-85.39	-99.3	-65.34	-108.55	-111.44	-88.24
Free Cash Flow Per Share	-0.77	-1.20	-0.94	-2.19	-2.28	-1.92
Gross Margin	86.34%	75.03%	64.76%	-	-278.96%	-106.76%
Operating Margin	-288.34%	-290.68%	-329.30%	-669.83%	-416.56%	-179.39%
Profit Margin	-289.44%	-292.08%	-295.96%	-638.34%	-412.19%	-183.23%
Free Cash Flow Margin	-243.71%	-276.24%	-183.61%	-522.96%	-358.36%	-192.73%
EBITDA	-99.45	-102.53	-115.36	-137.15	-127.86	-80.64
EBITDA Margin	-283.82%	-285.23%	-	-	-	-176.13%
D&A For EBITDA	1.58	1.96	1.82	1.88	1.68	1.49
EBIT	-101.03	-104.49	-117.18	-139.03	-129.53	-82.13
EBIT Margin	-288.34%	-290.68%	-	-	-	-179.39%

SEC Filings: 10-K · 10-Q